


CM03

Cat. No.:	HY-121862	
CAS No.:	2101208-44-8	
Molecular Formula:	C ₃₄ H ₄₄ N ₆ O ₆	
Molecular Weight:	632.75	
Target:	DNA/RNA Synthesis	
Pathway:	Cell Cycle/DNA Damage	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2 mg/mL (3.16 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.5804 mL	7.9020 mL	15.8040 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CM03 is a potent DNA G-quadruplexes (G4s) ligand. CM03 can stabilise G4s, downregulating more G4-containing genes as well as increasing incidence of double-strand break events (DSBs) due to torsional strain on DNA and chromatin structure. CM03 has selective potency for pancreatic cancer cells^{[1][2]}.

IC₅₀ & Target

DNA synthesis^[1]

In Vitro

CM03 (0.4 μM; 24 or 48 h) increases the level of γ-H2AX protein when in combination with [SAHA](#) (HY-10221) in MIA PaCa-2 and PANC-1^[1].

CM03 (0-100 nM; 96 h) exhibits highly anti-proliferative activity against pancreatic cancer cell lines^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line: MIA PaCa-2 and PANC-1

Concentration: 0.4 μM

Incubation Time:	24 h for MIA PaCa-2, 48 h for PANC-1
Result:	Significantly increased the level of γ -H2AX protein when in combination with SAHA (HY-10221) (1 μ M).
Cell Proliferation Assay ^[2]	
Cell Line:	MIA PaCa-2, PANC-1, Capan-1 and BxPC-3
Concentration:	0-100 nM
Incubation Time:	96 h
Result:	Exhibited highly anti-proliferative activity against pancreatic cancer cell lines with GI ₅₀ s of 9.0 nM, 15.6 nM, 26.5 nM and 15.5 nM in MIA PaCa-2, PANC-1, Capan-1 and BxPC-3, respectively.

REFERENCES

[1]. Ahmed AA, et al. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells. *Molecules*. 2020 Nov 19;25(22):5407.

[2]. Ahmed AA, et al. Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models. *ACS Med Chem Lett*. 2020 Jul 16;11(8):1634-1644.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA